Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDS Biotechnology CorpPDSB · Entity 7939 | Director | June 28, 2019 | July 01, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDS Biotechnology Corp
Report date June 28, 2019 · Filed July 01, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right To Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $5.99 · Expires 2029-06-28 | Direct | 9,000 |
Reported balance
After 2019-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-28 · Grant · Acquired 9,000 · Balance 9,000 F1: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 41,861 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. |
| Common StockSEC Table I · non-derivative | IndirectFamily Trust | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 1,800 · Balance 0 F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.69 · Expires 2020-06-16 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 24,666 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.00 · Expires 2021-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.80 · Expires 2022-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.06 · Expires 2023-06-12 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 18,600 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.50 · Expires 2024-07-01 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 20,700 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.16 · Expires 2025-06-17 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-11-20 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $99.98 · Expires 2026-06-15 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-11-20 · Disposition to issuer · Disposed 11,000 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $121.04 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2019-11-20 · Disposition to issuer · Disposed 10,500 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.38 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2019-11-20 · Disposition to issuer · Disposed 13,266 · Balance 0 F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2019-11-20 · Disposition to issuer · Disposed 300 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2019-11-20 · Disposition to issuer · Disposed 970 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2019-11-20 · Disposition to issuer · Disposed 4,756 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2019-11-20 · Disposition to issuer · Disposed 2,068 · Balance 0 F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company.
F2: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
F3: This option was fully exercisable.
F4: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F5: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F6: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 2,068 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 15 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,068 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 4,756 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 14 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,756 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 970 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 13 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 970 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerRestricted Stock Unit · Derivative | 300 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 12 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 300 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F6 · price: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.exercise_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. F6 · derivative.expiration_date: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement and became vested. The converted restricted stock units will be settled as promptly as practicable following the Effective Time. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 11 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,500 | $0.00 Strike: $121.04 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 10 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,500 shares Expires 2027-06-14 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $99.98 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 9 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires 2026-06-15 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $112.16 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 8 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-17 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 20,700 | $0.00 Strike: $88.50 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 7 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,700 shares Expires 2024-07-01 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 18,600 | $0.00 Strike: $59.06 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 6 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,600 shares Expires 2023-06-12 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 18,600 | $0.00 Strike: $31.80 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 5 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,600 shares Expires 2022-06-13 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 18,600 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 4 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,600 shares Expires 2021-06-15 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerStock Option (right to buy) · Derivative | 24,666 | $0.00 Strike: $27.69 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · derivative · entry 3 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,666 shares Expires 2020-06-16 F4 · price: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F3 · derivative.exercise_date: This option was fully exercisable. F4 · derivative.exercise_date: Upon the Effective Time, these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of CVRs, in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · nonDerivative · entry 2 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Family Trust Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. F2 · ownership.nature: The reporting person disclaims beneficial ownership of these securities and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 07:30 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Disposition to issuerCommon Stock | 41,861 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001371 · form4-11222019_071146.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), each share of Celgene common stock was converted into the right to receive (i) $50.00 in cash, (ii) one share of BMS common stock, and (iii) one contingent value right ("CVR") issued by BMS subject to and in accordance with the CVR agreement, dated November 20, 2019, by and between BMS and the Equiniti Trust Company. Read SEC document |
| June 28, 2019 Filed Jul 1, 2019 20:42 UTC | PDS Biotechnology Corp PDSB · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 9,000 | $0.00 Strike: $5.99 | $0.00 |
DisclosureSEC source: 0001127602-19-023235 · form4.xml · derivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2029-06-28 F1 · derivative.exercise_date: One third of the shares underlying the option shall vest upon each of the first, second, and third anniversaries of the date of grant, such that the option will be fully vested on June 28, 2022. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 2,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000728 · form4-06172019_040615.xml · derivative · entry 9 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,068 Underlying: Common Stock · 2,066 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 15, 2011 vested and settled for shares of the Company's common stock. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F10 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 2,068 shares on June 15, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F8 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F4 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 15, 2011 vested and settled for shares of the Company's common stock. F4 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 15, 2011 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000728 · form4-06172019_040615.xml · derivative · entry 8 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F8 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F3 · derivative.exercise_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. F3 · derivative.expiration_date: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 2,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000728 · form4-06172019_040615.xml · nonDerivative · entry 4 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: One-third of the restricted stock units granted to the reporting person on June 15, 2011 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000728 · form4-06172019_040615.xml · nonDerivative · entry 3 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,795 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: The remaining one-third of the restricted stock units granted to the reporting person on June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000728 · form4-06172019_040615.xml · derivative · entry 7 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F9 · derivative.exercise_price: The remainder of the restricted stock units will vest as follows: 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F8 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F2 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000728 · form4-06172019_040615.xml · nonDerivative · entry 2 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000728 · form4-06172019_040615.xml · derivative · entry 6 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970 Underlying: Common Stock · 484 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 485 shares on June 13, 2020 and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F8 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 484 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000728 · form4-06172019_040615.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,120 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 13, 2018 vested and settled for shares of the Company's common stock. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 4,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000665 · form4-06052019_040624.xml · derivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,756 Underlying: Common Stock · 4,756 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F3 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. F2 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 1,585 shares on June 3, 2020; 1,585 shares on June 3, 2021; and 1,586 shares on June 3, 2022. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 21:47 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-011927 · form4.xml · derivative · entry 3 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. F3 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F4 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| March 15, 2019 Filed Mar 18, 2019 21:47 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-011927 · form4.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of RSUs granted to the Reporting Person on August 14, 2018. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 24,666 | Not disclosed Strike: $22.47 | Not disclosed |
DisclosureSEC source: 0001415889-19-000144 · form4-02112019_040201.xml · derivative · entry 4 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,666 shares Expires 2019-06-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan). F3 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 23,466 | $87.29 | $2,048,323.67 |
DisclosureSEC source: 0001415889-19-000144 · form4-02112019_040201.xml · nonDerivative · entry 2 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,636 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $87.28 to $87.30, inclusive. The reporting person undertakes to provide Celgene Corporation (the "Company"), any security holder of the Company or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| February 07, 2019 Filed Feb 11, 2019 16:05 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 24,666 | $22.47 | $554,245.02 |
DisclosureSEC source: 0001415889-19-000144 · form4-02112019_040201.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2018 Filed Aug 15, 2018 12:03 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-025374 · form4.xml · derivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit. F2 · derivative.exercise_date: These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria. F3 · derivative.expiration_date: Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest. Read SEC document |
| June 19, 2018 Filed Jun 20, 2018 20:28 UTC | PDS Biotechnology Corp EDGE · Entity 7939 | GrantStock Option (Right To Purchase) · Derivative | 20,000 | $0.00 Strike: $1.10 | $0.00 |
DisclosureSEC source: 0001127602-18-021582 · form4.xml · derivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires not disclosed F1 · derivative.exercise_date: These options shall become exercisable upon the achievement of certain performance or time based criteria. F2 · derivative.expiration_date: These options expire on the third anniversary of the vesting date. Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000950 · form4-06182018_040615.xml · derivative · entry 3 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F1 · derivative.exercise_date: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| June 17, 2018 Filed Jun 18, 2018 16:00 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 334 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000950 · form4-06182018_040615.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The remaining one-third of the restricted stock units granted to the reporting person on June 17, 2015 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:13 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 2,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000935 · form4-06152018_010627.xml · derivative · entry 9 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,134 Underlying: Common Stock · 2,066 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 15, 2011 vested and such vested restricted stock units settled for shares of the Company's common stock. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F12 · derivative.exercise_price: The remainder of the restricted stock units will vest in annual installments as follows: 2,066 shares on June 15, 2019 and 2,068 shares on June 15, 2020. Vested shares will be delivered promptly to the reporting person after the vesting date. F13 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the Company's 2008 Stock Incentive Plan). F3 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 15, 2011 vested and such vested restricted stock units settled for shares of the Company's common stock. F3 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 15, 2011 vested and such vested restricted stock units settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:13 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000935 · form4-06152018_010627.xml · derivative · entry 8 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375 Underlying: Common Stock · 375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F11 · derivative.exercise_price: The remainder of the restricted stock units will vest on June 15, 2019. Vested shares will be delivered to the reporting person promptly after the vesting date. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F2 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. F2 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:13 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 2,066 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000935 · form4-06152018_010627.xml · nonDerivative · entry 3 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,102 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: One-third of the restricted stock units granted to the reporting person on June 15, 2011 vested and such vested restricted stock units settled for shares of the Company's common stock. Read SEC document |
| June 15, 2018 Filed Jun 15, 2018 16:13 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 375 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000935 · form4-06152018_010627.xml · nonDerivative · entry 2 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,036 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: One-third of the restricted stock units granted to the reporting person June 15, 2016 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:13 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000935 · form4-06152018_010627.xml · derivative · entry 7 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F10 · derivative.exercise_price: The remainder of the restricted stock units will vest in two annual installments as follows: 300 shares on June 14, 2019 and 300 shares on June 14, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 16:13 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000935 · form4-06152018_010627.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on June 14, 2017 vested and settled for shares of the Company's common stock. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:13 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantStock Option (right to buy) · Derivative | 13,266 | $0.00 Strike: $77.38 | $0.00 |
DisclosureSEC source: 0001415889-18-000935 · form4-06152018_010627.xml · derivative · entry 6 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,266 Underlying: Common Stock · 13,266 shares Expires 2028-06-13 F9 · price: The option was issued pursuant to the Company's 2017 Stock Incentive Plan. F8 · derivative.exercise_date: Option is immediately exercisable and will vest on the earlier of June 13, 2019 or the day preceding the date of the next stockholder meeting. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 16:13 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | GrantRestricted Stock Unit · Derivative | 1,454 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-000935 · form4-06152018_010627.xml · derivative · entry 5 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,454 Underlying: Common Stock · 1,454 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F7 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan. F6 · derivative.exercise_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. F6 · derivative.expiration_date: The restricted stock units will vest in three annual installments as follows: 484 shares on June 13, 2019; 485 shares on June 13, 2020; and 485 shares on June 13, 2021. Vested shares will be delivered to the reporting person promptly after the vesting date. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 27,750 | Not disclosed Strike: $30.01 | Not disclosed |
DisclosureSEC source: 0001415889-18-000872 · form4-06052018_040601.xml · derivative · entry 4 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,750 shares Expires 2018-06-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The option was issued pursuant to the Company's 1995 Non-Employee Director's Incentive Plan. F3 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 17,750 | $78.96 | $1,401,540.00 |
DisclosureSEC source: 0001415889-18-000872 · form4-06052018_040601.xml · nonDerivative · entry 2 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,361 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $78.61 to $79.16, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4. Read SEC document |
| June 04, 2018 Filed Jun 5, 2018 16:15 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 27,750 | $30.01 | $832,777.50 |
DisclosureSEC source: 0001415889-18-000872 · form4-06052018_040601.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 16:22 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionStock Option (right to buy) · Derivative | 9,250 | Not disclosed Strike: $27.18 | Not disclosed |
DisclosureSEC source: 0001209191-18-019209 · doc4.xml · derivative · entry 4 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,250 shares Expires 2018-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The option was issued pursuant to the Company's 1995 Non-Employee Directors' Incentive Plan. F3 · derivative.exercise_date: The option was fully exercisable. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 16:22 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | SaleCommon Stock | 9,250 | $92.01 | $851,092.50 |
DisclosureSEC source: 0001209191-18-019209 · doc4.xml · nonDerivative · entry 2 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,361 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold by the reporting person in multiple transactions at prices ranging from $91.46 to $92.47, inclusive. The reporting person undertakes to provide to Celgene Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 16:22 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 9,250 | $27.18 | $251,415.00 |
DisclosureSEC source: 0001209191-18-019209 · doc4.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 19:33 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionRestricted Stock Unit · Derivative | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043766 · doc4.xml · derivative · entry 3 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 734 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's common stock. F4 · price: The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan (formerly known as the 2008 Stock Incentive Plan (as amended and restated on April 15, 2015)). F1 · derivative.exercise_date: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. F1 · derivative.expiration_date: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 19:33 UTC | CELGENE CORP /DE/ CELG · Entity 15781 | Exercise / conversionCommon Stock | 734 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-043766 · doc4.xml · nonDerivative · entry 1 LOUGHLIN JAMES J · CIK 0001276550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-third of the restricted stock units granted to the reporting person on July 1, 2014 vested and such vested portion of the restricted stock units settled for shares of the Company's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.